Selskabets formål er at drive virksomhed indenfor forskning, udvikling og markedsføring af produkter til brug for diagnosticering, behandling og/eller forebyggelse af hæmatologiske sygdomme med risiko for øget blødning eller udvikling af blodpropper.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | - | - | - | 104 t. | 36 | |
CVR: 40837590
Previous names: Ebumab Hemophilia ApS
Compared to 130 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
Laura Anne Tadvalkar left the board
Jørgen Søberg Petersen left the board
Daniel Becker left the board
Uya Chuluunbaatar left the board
Joseph Anderson left the board
registered with 100% ownership
Joseph Anderson joined the board
Mårten Steen left the board
Companies in the same industry and area
CVR 38402056
CVR 39859173
CVR 39880377
CVR 42057428
CVR 43432583
companydata.dk